secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2026-08-12T12:45:32+00:00
Accession:  0001493152-26-037257
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q2 2026 revenue flat at $961K; net loss $2.12M, cash down to $4.79M
--------------------------------------------------------------------------

- Revenue $961,138, down 0.6% YoY; grant revenue up $334K, R&D revenue down $89.6K.
- Net loss $2,123,884 ($0.06/share) vs $1,793,774 ($0.06/share) a year ago.
- Cash and investments $4.79M at June 30, down from $8.59M at Dec 31, 2025.
- Commercial progress: shipments of 6 recombinant proteins, pilot sales for cultivated meat, IBT Bioservices OEM shipments, Proliant Albufree DX launch.
- Transferrin productivity up ~80% at pilot scale; Gates Foundation RSV/malaria mAb programs advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000149315226037257/0001493152-26-037257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000149315226037257/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer